Literature DB >> 18625769

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.

Yigong Ge1, Donald Biek, George H Talbot, Daniel F Sahm.   

Abstract

This study evaluated the in vitro activity of ceftaroline, a novel cephalosporin with broad-spectrum activity against gram-negative and -positive pathogens, against 4,151 recent clinical isolates collected in the United States. Ceftaroline was very potent against bacteria found in community- and hospital-acquired infections, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococcus pneumoniae, and common Enterobacteriaceae spp.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18625769      PMCID： PMC2533496          DOI： 10.1128/AAC.00149-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.

Authors:  Inmaculada A Herrero; Nicolas C Issa; Robin Patel
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

Review 2.  Inhibitors of efflux pumps in Gram-negative bacteria.

Authors:  Jean-Marie Pagès; Muriel Masi; Jacques Barbe
Journal:  Trends Mol Med       Date:  2005-08       Impact factor: 11.951

Review 3.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

4.  Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Authors:  Helio S Sader; Thomas R Fritsche; Koné Kaniga; Yigong Ge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 5.  Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).

Authors:  H Giamarellou
Journal:  Clin Microbiol Infect       Date:  2005-07       Impact factor: 8.067

Review 6.  Community-acquired pneumonia.

Authors:  J G Bartlett; L M Mundy
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Genome and virulence determinants of high virulence community-acquired MRSA.

Authors:  Tadashi Baba; Fumihiko Takeuchi; Makoto Kuroda; Harumi Yuzawa; Ken-ichi Aoki; Akio Oguchi; Yoshimi Nagai; Natsuko Iwama; Kazuyuki Asano; Timothy Naimi; Hiroko Kuroda; Longzhu Cui; Kenji Yamamoto; Keiichi Hiramatsu
Journal:  Lancet       Date:  2002-05-25       Impact factor: 79.321

8.  TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties.

Authors:  Tomoyasu Ishikawa; Nobuyuki Matsunaga; Hiroyuki Tawada; Noritaka Kuroda; Yutaka Nakayama; Yukio Ishibashi; Mitsumi Tomimoto; Yukihiro Ikeda; Yoshihiko Tagawa; Yuji Iizawa; Kenji Okonogi; Shohei Hashiguchi; Akio Miyake
Journal:  Bioorg Med Chem       Date:  2003-05-29       Impact factor: 3.641

9.  In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

Authors:  Yuji Iizawa; Junko Nagai; Tomoyasu Ishikawa; Shohei Hashiguchi; Masafumi Nakao; Akio Miyake; Kenji Okonogi
Journal:  J Infect Chemother       Date:  2004-06       Impact factor: 2.211

10.  Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages.

Authors:  Robin A Howe; Alastair Monk; Mandy Wootton; Timothy R Walsh; Mark C Enright
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883
View more
  38 in total

1.  In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.

Authors:  Dora E Wiskirchen; Jared L Crandon; Guilherme H Furtado; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

Review 2.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

3.  In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

Review 4.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

5.  Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

Authors:  Sandra S Richter; Kristopher P Heilmann; Cassie L Dohrn; Fathollah Riahi; Andrew J Costello; Jennifer S Kroeger; Donald Biek; Ian A Critchley; Daniel J Diekema; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

6.  In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model.

Authors:  Amira A Bhalodi; Jared L Crandon; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

7.  Postantibiotic effect of ceftaroline against gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

Review 8.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 9.  Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit.

Authors:  Lee P Skrupky; Scott T Micek; Marin H Kollef
Journal:  Crit Care       Date:  2009-10-08       Impact factor: 9.097

10.  Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.

Authors:  Yigong Ge; David Maynard; Douglas E Rickert
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.